Hepatocellular carcinoma (HCC) is one of the deadliest cancers in the world with a five-year survival rate of less than 20%. Nonetheless, selecting an appropriate therapeutic agent to inhibit the development of hepatoma cells is still a challenge. Bufalin, a component of the traditional Chinese medicine Chansu, has been shown to inhibit the proliferation, invasion and metastasis of HCC through various signaling pathways. In addition, bufalin and sorafenib demonstrate a synergistic effect in cancer therapeutics. This review highlighted on several focal signaling pathways involved in the inhibitory effects of bufalin on HCC and its synergistic mechanisms with sorafenib. The immunotherapy effect of bufalin has also been discussed as a novel property.
CITATION STYLE
Jiang, H. Y., Zheng, H. M., Xia, C., Li, X., Wang, G., Zhao, T., … Liu, Y. (2022). The Research Progress of Bufalin in the Treatment of Hepatocellular Carcinoma. OncoTargets and Therapy. Dove Medical Press Ltd. https://doi.org/10.2147/OTT.S333233
Mendeley helps you to discover research relevant for your work.